Impacts of RETN genetic polymorphism on breast cancer development

Abstract

The adipokine resistin is linked with obesity, inflammation and various cancers, including breast cancer. This study sought to determine whether certain polymorphisms in the gene encoding resistin, RETN, increase the risk of breast cancer susceptibility. We analyzed levels of resistin expression in breast cancer tissue and samples from The Cancer Genome Atlas database. We also examined associations between four RETN single nucleotide polymorphisms (SNPs; rs3745367, rs7408174, rs1862513 and rs3219175) and breast cancer susceptibility in 515 patients with breast cancer and 541 healthy women without cancer. Compared with wild-type (GG) carriers, those carrying the AG genotype of the RETN SNP rs3219175 and those carrying at least one A allele in the SNP rs3219175 had a higher chance of developing breast cancer (adjusted odds ratio, AOR: 1.295, 95% confidence intervals, CI: 1.065-1.575 and 2.202, 1.701-2.243, respectively). When clinical aspects and the RETN SNP rs7408174 were examined in the breast cancer cohort, the CT genotype was linked to late-stage disease, while women with luminal A disease and at least one C allele were likely to progress to stage III/IV disease and to develop highly pathological grade III disease. Moreover, resistin-positive individuals were at greater risk than resistin-negative individuals for developing pathological grade III disease (OR: 5.020; 95% CI: 1.380-18.259). This study details risk associations between resistin and RETN SNPs in breast cancer susceptibility in Chinese Han women.

Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer

“…Our previous study found upregulated resistin expression in breast cancer tissue than in normal breast tissue [8], but in that study, we did not analyze the relationship between the high expression of resistin and the clinicopathological characteristics of breast cancer patients. In this study, we observed that both positive and strongly positive rates of resistin expression are significantly higher in breast cancer tissue specimens compared with normal breast tissue and that both positive and strongly positive resistin expressions are significantly associated with a number of clinicopathological parameters in breast cancer patients.…”

“…Resistin and EGFR expression staining intensity was scored on a 4-point scale from 0 (negative) to 1 (weak), 2 (moderate), or 3 (strong) [18]. A case was recorded as resistin-positive if the cytoplasmic staining intensity of positive invasive cancer cells was 2 or 3; 3 was deemed strongly positive [8]. Cases were EGFR-positive when ≥10% of the invasive tumor cells had a membranous staining intensity of 1, 2, or 3; 2 and 3 were considered to be strongly positive [11].…”

“…Significant correlations have been observed between high resistin expression in breast cancer tissue and tumor stage, tumor size, lymph node metastasis, estrogen receptor (ER) status, and poor survival [7]. We have previously reported finding much higher levels of resistin expression in breast cancer tissue than in normal breast tissue [8], but in that study, we did not analyze the relationship between the high expression of resistin and the clinicopathological characteristics of breast cancer patients.…”

Current Landscape: The Mechanism and Therapeutic Impact of Obesity for Breast Cancer

“…Decreasing levels of adiponectin in the obese woman may reduce the beneficial effects of adiponectin on BC, including inhibiting BC cell proliferation or stimulating apoptosis of BC cells. Novel therapeutic approaches toward adiponectin could be (44). They also proved the association between polymorphisms of the RETN gene and susceptibility for BC.…”

“…Wang et al. identified high levels of resistin in BC patients in Chinese Han women, and resistin might be a predictive marker in BC treatment ( 44 ). They also proved the association between polymorphisms of the RETN gene and susceptibility for BC.…”